Literature DB >> 2506138

Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells.

M Maio1, B Gulwani, A Morgano, S Ferrone.   

Abstract

Tumor necrosis factor (TNF-alpha) was compared to immune interferon (IFN-gamma) for its ability to modulate the expression and shedding of HLA antigens, of intercellular adhesion molecule I (ICAM I) and of high-molecular-weight melanoma-associated antigen (HMW MAA) by a panel of melanoma cell lines. The latter included the melanoma cell line MeWo and its metastatic variant MeM 50-10, which display differential susceptibility to modulation of HLA class-II antigens by IFN-gamma and the cell lines SK-MEL-93-DX-2 and SK-MEL-93-DX-3, which originated from anatomically distinct metastases in patient DX. TNF-alpha enhanced the expression of HLA class-I antigens on all 7 melanoma cell lines tested, although to a lower extent than IFN-gamma and the combination of IFN-gamma and TNF-alpha. TNF-alpha displayed a differential effect on the expression of HLA class-II antigens by the 7 melanoma cell lines: it enhanced it on 3 out of the 4 cell lines with constitutive expression of HLA class-II antigens and induced them on 1 of 3 cell lines without detectable expression of these antigens. The effects of IFN-gamma were different since it enhanced HLA class-II antigens on the 4 cell lines with constitutive expression of these antigens and induced them on 2 out of the remaining 3 lines. Interestingly, both TNF-alpha and IFN-gamma enhanced the expression of HLA class-II antigens by SK-MEL-93-DX-3 cells. On the other hand only TNF-alpha induced the expression of HLA class-II antigens by MeWo cells and only IFN-gamma induced such expression by MeM 50-10 cells and by SK-MEL-93-DX-2 cells. The effect of the combination of TNF-alpha and IFN-gamma was similar to that of the individual cytokines. Both TNF-alpha and IFN-gamma displayed a differential effect on the expression of the gene products of the HLA-D region by the melanoma cell lines. Northern blot analysis with HLA-DR beta-, DQ beta- and DP beta-specific probes suggests that the modulation of HLA class-II antigens by both cytokines reflects transcriptional and post-transcriptional events. TNF-alpha enhanced the expression of ICAM-I on all the melanoma cell lines, although to a lower extent than IFN-gamma and the combination of IFN-gamma and TNF-alpha. Lastly, neither TNF-alpha nor IFN-gamma displayed a marked effect on the expression of HMW-MAA by the melanoma cell lines tested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506138     DOI: 10.1002/ijc.2910440330

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.

Authors:  R Landmann; U Keilholz; C Scheibenbogen; M Brockhaus; H Gallati; H Denz; M Bargetzi; C Ludwig
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

2.  Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10.

Authors:  M Maio; B Gulwani; S Tombesi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.

Authors:  T Morisaki; D L Morton; A Uchiyama; D Yuzuki; A Barth; D S Hoon
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

4.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

Authors:  C M D'Urso; Z G Wang; Y Cao; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

5.  Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells.

Authors:  D S Hoon; Y Hayashi; T Morisaki; L J Foshag; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

6.  Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy.

Authors:  K M McAveney; L G Gomella; E C Lattime
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

7.  Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.

Authors:  G G Hillman; R K Puri; M A Kukuruga; J E Pontes; G P Haas
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

8.  Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.

Authors:  Carol M Amato; Jennifer D Hintzsche; Keith Wells; Allison Applegate; Nicholas T Gorden; Victoria M Vorwald; Richard P Tobin; Kelsey Nassar; Yiqun G Shellman; Jihye Kim; Theresa M Medina; Matthew Rioth; Karl D Lewis; Martin D McCarter; Rene Gonzalez; Aik-Choon Tan; William A Robinson
Journal:  Cancers (Basel)       Date:  2020-07-17       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.